Travere Therapeutics Inc (NASDAQ: TVTX) kicked off on Tuesday, up 5.18% from the previous trading day, before settling in for the closing price of $14.49. Over the past 52 weeks, TVTX has traded in a range of $7.36-$25.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -3.34%. While this was happening, its average annual earnings per share was recorded 74.79%. With a float of $87.50 million, this company’s outstanding shares have now reached $88.79 million.
The extent of productivity of a business whose workforce counts for 385 workers is very important to gauge. In terms of profitability, gross margin is 92.23%, operating margin of -81.81%, and the pretax margin is -82.6%.
Travere Therapeutics Inc (TVTX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.47%, while institutional ownership is 112.64%. The most recent insider transaction that took place on May 05 ’25, was worth 37,553. In this transaction CHIEF FINANCIAL OFFICER of this company sold 1,784 shares at a rate of $21.05, taking the stock ownership to the 93,126 shares. Before that another transaction happened on May 05 ’25, when Company’s CHIEF EXECUTIVE OFFICER sold 18,924 for $21.05, making the entire transaction worth $398,350. This insider now owns 419,173 shares in total.
Travere Therapeutics Inc (TVTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 74.79% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Take a look at Travere Therapeutics Inc’s (TVTX) current performance indicators. Last quarter, stock had a quick ratio of 2.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.80, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach 0.59 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
The latest stats from [Travere Therapeutics Inc, TVTX] show that its last 5-days average volume of 1.35 million was inferior to 1.71 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 49.08%.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 18.82%, which indicates a significant decrease from 77.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.11% in the past 14 days, which was lower than the 71.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.88, while its 200-day Moving Average is $17.81. Now, the first resistance to watch is $15.53. This is followed by the second major resistance level at $15.83. The third major resistance level sits at $16.41. If the price goes on to break the first support level at $14.65, it is likely to go to the next support level at $14.07. The third support level lies at $13.77 if the price breaches the second support level.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
The company with the Market Capitalisation of 1.35 billion has total of 88,805K Shares Outstanding. Its annual sales at the moment are 233,180 K in contrast with the sum of -321,550 K annual income. Company’s last quarter sales were recorded 81,730 K and last quarter income was -41,230 K.
